1. Home
  2. XOMAO vs REFR Comparison

XOMAO vs REFR Comparison

Compare XOMAO & REFR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • XOMAO
  • REFR
  • Stock Information
  • Founded
  • XOMAO N/A
  • REFR 1965
  • Country
  • XOMAO United States
  • REFR United States
  • Employees
  • XOMAO 13
  • REFR N/A
  • Industry
  • XOMAO Biotechnology: Pharmaceutical Preparations
  • REFR Multi-Sector Companies
  • Sector
  • XOMAO Health Care
  • REFR Miscellaneous
  • Exchange
  • XOMAO Nasdaq
  • REFR Nasdaq
  • Market Cap
  • XOMAO N/A
  • REFR N/A
  • IPO Year
  • XOMAO N/A
  • REFR N/A
  • Fundamental
  • Price
  • XOMAO $25.35
  • REFR $1.74
  • Analyst Decision
  • XOMAO
  • REFR
  • Analyst Count
  • XOMAO 0
  • REFR 0
  • Target Price
  • XOMAO N/A
  • REFR N/A
  • AVG Volume (30 Days)
  • XOMAO N/A
  • REFR 47.4K
  • Earning Date
  • XOMAO N/A
  • REFR 07-31-2025
  • Dividend Yield
  • XOMAO N/A
  • REFR N/A
  • EPS Growth
  • XOMAO N/A
  • REFR N/A
  • EPS
  • XOMAO N/A
  • REFR N/A
  • Revenue
  • XOMAO N/A
  • REFR $1,581,929.00
  • Revenue This Year
  • XOMAO N/A
  • REFR N/A
  • Revenue Next Year
  • XOMAO N/A
  • REFR N/A
  • P/E Ratio
  • XOMAO N/A
  • REFR N/A
  • Revenue Growth
  • XOMAO N/A
  • REFR 62.28
  • 52 Week Low
  • XOMAO N/A
  • REFR $0.93
  • 52 Week High
  • XOMAO N/A
  • REFR $2.39
  • Technical
  • Relative Strength Index (RSI)
  • XOMAO 56.82
  • REFR 48.88
  • Support Level
  • XOMAO $25.25
  • REFR $1.82
  • Resistance Level
  • XOMAO $25.35
  • REFR $2.05
  • Average True Range (ATR)
  • XOMAO 0.07
  • REFR 0.12
  • MACD
  • XOMAO 0.01
  • REFR -0.05
  • Stochastic Oscillator
  • XOMAO 95.00
  • REFR 18.60

About XOMAO AGNC Investment Corp.

XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.

Share on Social Networks: